Entering text into the input field will update the search result below

Pure Bioscience, Inc. (PURE) Gets Good News on SDC

May 19, 2011 5:45 PM ETPURE
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Seeking Alpha Analyst Since 2008

QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net.

PURE Bioscience, developers of bioscience products for combating stubborn bacteria such as Staph (MRSA), announced today that its patented antimicrobial product SDC (silver dihydrogen citrate) has been shown to be effective based upon tests conducted by the University of Medicine & Dentistry of New Jersey. The tests demonstrated SDC’s effectiveness against bacterial films, common in any nutrient-sufficient ecosystems, such as oral cavities.

Dr. Narayanan Ramasubbu, Associate Professor with the Department of Oral Biology at the university, described the study and its results. “We have used SDC against single species biofilms of Aggregatibacter actinomycetemcomitans, a causative agent in localized aggressive periodontitis, and S. epidermidis, a pathogen associated with hospital settings. Our results show that these bacteria in the biofilm state are killed within minutes at 30 ppm of SDC. Not only did SDC kill biofilm bacteria but also it inhibited the biofilm formation at levels as low as 1.5 ppm in a citrate-containing medium.”

According to Dr. Ramasubbu, biofilms play a role in the pathogenesis of dental caries, periodontitis, infective endocarditis, cystic fibrosis, pneumonia, prostatitis, osteomyelitis, otitis media, infectious kidney stones, and other chronic infections, and that they can be comprised of a single microbial species or multiple microbial species, requiring very specific, highly effective, and environmentally safe agents that can adapt to resistance.

PURE’s President and CEO, Michael Krall, commented on the development. “SDC’s ability to eliminate and even prevent biofilm presents a phenomenal market opportunity for PURE. We’re directing ongoing research projects on biofilm not only in public health, but also in industrial environments, including food processing, and oil and gas, as we begin to present SDC as a viable solution to this costly and dangerous problem.”

SDC is an electrolytically generated source of stabilized ionic silver, which can be joined with other compounds to provide superior antimicrobial efficacy with residual protection while mitigating bacterial resistance.

For additional information, visit the company’s website at PUREBio.com

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.